Pfizer Inc (PFE)vsSouthern Copper Corporation (SCCO)
PFE
Pfizer Inc
$27.28
+1.19%
HEALTHCARE · Cap: $153.36B
SCCO
Southern Copper Corporation
$165.49
+3.51%
BASIC MATERIALS · Cap: $131.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 366% more annual revenue ($62.58B vs $13.42B). SCCO leads profitability with a 32.3% profit margin vs 12.4%. SCCO appears more attractively valued with a PEG of 5.41. SCCO earns a higher WallStSmart Score of 65/100 (B-).
PFE
Hold49
out of 100
Grade: D+
SCCO
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-194.9%
Fair Value
$9.25
Current Price
$27.28
$18.03 premium
Margin of Safety
+13.4%
Fair Value
$243.36
Current Price
$165.49
$77.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Generating 4.5B in free cash flow
Every $100 of equity generates 43 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 54.5%
Revenue surging 39.0% year-over-year
Earnings expanding 60.4% YoY
Large-cap with strong market position
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.2%
Earnings declined 21.3%
Premium valuation, high expectations priced in
Trading at 12.4x book value
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : PFE
The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.
Bull Case : SCCO
The strongest argument for SCCO centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 54.5%. Revenue growth of 39.0% demonstrates continued momentum.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : SCCO
The primary concerns for SCCO are P/E Ratio, Price/Book, PEG Ratio.
Key Dynamics to Monitor
PFE profiles as a declining stock while SCCO is a growth play — different risk/reward profiles.
SCCO carries more volatility with a beta of 1.08 — expect wider price swings.
SCCO is growing revenue faster at 39.0% — sustainability is the question.
PFE generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
SCCO scores higher overall (65/100 vs 49/100), backed by strong 32.3% margins and 39.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Southern Copper Corporation
BASIC MATERIALS · COPPER · USA
Southern Copper Corporation is engaged in the extraction, exploration, smelting and refining of copper and other minerals in Peru, Mexico, Argentina, Ecuador and Chile.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?